RxDoctor Payments Data

George Koromia, MD

Cardiovascular Disease · Sandusky, OHNPI 1952780975

Payments from drug & device makers

$2,024in general payments, 2019–2025

Across 69 payments — averaging $29.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$326
  • AstraZeneca$275
  • E.r. Squibb & Sons, L.L.C.$266
  • Boston Scientific$209
  • Amgen$176
  • Boehringer Ingelheim$128
  • plus $643 from 11 others

What the payments were for

  • Food & beverage$1,86292%
  • Education$1628%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,024 in reported general payments places this provider in the 50th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$77,434
Medicare patients
837
Services billed
1,596

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$72,842
JardianceEmpagliflozin44$41,940
EntrestoSacubitril/Valsartan40$33,648
XareltoRivaroxaban17$15,343
BrilintaTicagrelor16$13,368
Metoprolol Succinate187$1,755
Diltiazem 24hr Er (Cd)Diltiazem Hcl47$843
Amiodarone Hcl29$587
Carvedilol76$431
Flecainide Acetate13$429
Isosorbide Mononitrate ErIsosorbide Mononitrate42$315
Atorvastatin Calcium58$309
Losartan Potassium33$297
Rosuvastatin Calcium23$294
Lisinopril56$251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$94$72,84276 claims
Boehringer IngelheimJardiance$128$41,94044 claims
NovartisEntresto$92$33,64840 claims
Johnson & JohnsonXarelto$34$15,34317 claims
AstraZenecaBrilinta$275$13,36816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Sandusky

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →